Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism.
Betrixaban
Extended duration prophylaxis
Re-admission
Venous thromboembolism
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
accepted:
10
01
2021
pubmed:
10
4
2021
medline:
27
1
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
Patients hospitalized for an acute medical illness remain at risk of developing venous thromboembolism (VTE) post-discharge. Betrixaban, an oral direct Factor Xa inhibitor, is approved for extended VTE thromboprophylaxis in acutely ill medical patients. The primary objective of this study was to evaluate patients re-admitted with VTE within 30 days of discharge to determine if they would have been eligible for extended duration VTE prophylaxis during the index admission. We used three different sets of eligibility criteria: the APEX study criteria, the Bevyxxa® (betrixaban) package insert, and Mass General Brigham HealthCare System's Center for Drug Policy Guidelines. A secondary aim was to describe the reasons for ineligibility. Within 30 days of the index hospital admission, 226 patients were re-admitted with new VTE between January 2017 and December 2018. Of these, 134 (59%) were excluded based on pre-defined exclusion criteria. Of the remaining 92, 22 patients (23.9%) were eligible based on the APEX study criteria, 26 patients (28.2%) based on Mass General Brigham HealthCare System's Center for Drug Policy Guidelines, and 92 patients (100%) based on the Bevyxxa® package insert. There were 22 patients (23.9%) who were eligible for VTE prophylaxis with betrixaban based on all three criteria. Appropriate betrixaban use may have prevented some of the VTE events and re-admissions that occurred within 30 days of initial hospital discharge.
Identifiants
pubmed: 33835335
doi: 10.1007/s11239-021-02376-9
pii: 10.1007/s11239-021-02376-9
doi:
Substances chimiques
Anticoagulants
0
Benzamides
0
Pharmaceutical Preparations
0
Pyridines
0
betrixaban
74RWP7W0J9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22-29Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Geerts WH, Bergqvist D, on behalf of American College of Chest Physicians et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8
doi: 10.1378/chest.08-0656
Beckman MG, Hooper WC et al (2007) Venous thromboembolism A public health concern. Arch Intern Med 167(14):1471–1475
doi: 10.1001/archinte.167.14.1471
Heit JA, Crusan DJ et al (2017) Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood 130(2):109–114
doi: 10.1182/blood-2016-12-758995
Amin AN, Varker H et al (2012) Duration of venous thromboembolism risk across a continuum in medically Ill hospitalized patients. J Hosp Med 7:231–238
doi: 10.1002/jhm.1002
Anderson FA, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107:9–16
doi: 10.1161/01.CIR.0000078469.07362.E6
Hull R, Schellong SM et al (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility. Ann Intern Med 153:8–18
doi: 10.7326/0003-4819-153-1-201007060-00004
Cohen AT, Spiro TE et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523
doi: 10.1056/NEJMoa1111096
Goldhaber SZ, Leizorovicz A et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177
doi: 10.1056/NEJMoa1110899
Kearon C, Akl EA et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352
doi: 10.1016/j.chest.2015.11.026
Schünemann HJ, Cushman M et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2(22):3198–3225
doi: 10.1182/bloodadvances.2018022954
Cohen AT, Harrington RA et al (2016) Extended thromboprophylaxis with betrixaban in acutely Ill medical patients. N Engl J Med 375:534–544
doi: 10.1056/NEJMoa1601747
Bevyxxa (Betrixaban) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf . Accessed 8 April 2021
Partners HealthCare Center for Drug Policy (2017) Betrixaban (Bevyxxa®) guidelines. Internal guideline (Partners HealthCare Center for Drug Policy). Unpublished
Goldhaber SZ (2020) Thromboembolism prophylaxis for patients discharged from the hospital. JACC 75(25):3148–3150
doi: 10.1016/j.jacc.2020.05.023
Martin AC, Huang W, Goldhaber SZ et al (2019) Estimation of acutely Ill medical patients at venous thromboembolism risk eligible for extended thromboprophylaxis using APEX criteria in US Hospital. Clin Appl Thromb Hemost 25:1–5
doi: 10.1177/1076029619880008
Spyropoulos A, Ageno W et al (2018) Rivaroxaban for thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med 379:1118–1127
doi: 10.1056/NEJMoa1805090
Spyropoulos A, Lipardi C et al (2019) Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. CATH 25:1–9
Xarelto (rivaroxaban) prescribing information. Janssen Pharmaceuticals, Inc., Titusville, NJ, USA (2020). https://www.janssenlabels.com/package-insert/product-monograph/prescribinginformation/XARELTO-pi.pdf . Accessed 8 April 2021